Printer Friendly

United States : PharmaCyte Biotech Closer to Submitting IND by Successfully Completing Encapsulation of Second Manufacturing Run of Clinical Trial Product.

PharmaCyte Biotech, Inc. a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, is closer to submitting an Investigational New Drug application (IND) to the U.S. Food & Drug Administration (FDA). PharmaCyte announced today that its partner, Austrianova Singapore (Austrianova), has successfully completed encapsulation of the cells from PharmaCytes Master Cell Bank (MCB) in the second of two staggered and back-to-back manufacturing runs for the production of PharmaCytes clinical trial product. This product will be used for PharmaCytes planned clinical trial in patients with locally advanced, inoperable pancreatic cancer (LAPC).

PharmaCytes Chief Executive Officer, Kenneth L. Waggoner, commented, The encapsulation process was performed last week at Austrianovas manufacturing facility in Thailand. After reviewing the first pictures of the encapsulated cells, were confident that this manufacturing run is progressing as well as our first successful manufacturing run. We are anxiously awaiting the completion of the second of the two back-to-back manufacturing runs and the results from the FDA required testing on each of those runs. Once the information from that testing is available, it will be incorporated into our Investigational New Drug application (IND) for submission to the FDA.

Most of the work needed for PharmaCyte to submit an IND to the FDA has been completed. The rate limiting factor is and always has been for Austrianova to complete successfully two back-to-back manufacturing runs. During PharmaCytes recent shareholder update call, the company reported on Austrianovas work to encapsulate successfully PharmaCytes genetically modified human cells that will be used to treat patients suffering from LAPC.

After months of extensive research and development (R&D) by a team of experts from Austrianova and PharmaCyte, a total of eight different changes were made to the manufacturing process. It was not until the eighth and final change was made that the encapsulated cells grew as well in Austrianovas manufacturing facility in Thailand as they grew at Austrianovas R&D facility in Singapore.

Once the recently encapsulated cells in this second of two manufacturing runs have completely filled the capsules, they will be placed into PharmaCytes clinical trial syringes and then frozen. A representative sample of those syringes will be thawed and undergo the FDA required release testing. All release testing related to safety of the encapsulated cells is being outsourced by PharmaCyte to independent third-party laboratories in Europe. All release testing related to functionality of the encapsulated cells is being handled by Austrianova at its GMP facility in Thailand.

[c] 2019 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Nov 11, 2019
Previous Article:United States : OraSure Technologies to Present at Stephens 2019 Nashville Investment Conference.
Next Article:Switzerland : Genentechs Risdiplam Meets Primary Endpoint In Pivotal SUNFISH Trial in People With Type 2 or 3 Spinal Muscular Atrophy.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters